Piramal Pharma Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore)
Piramal Pharma Ltd · Outcome · 28 Oct 2026, 2:23 am
Piramal Pharma Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore) ■ Revenue: 2,617 (+28.1% YoY | +15.3% QoQ) ■ EBITDA: 349 (+119.8% YoY | +78.7% QoQ) ■ EBITDA Margin (%): 13.3 (+556 bps YoY | +473 bps QoQ) ■ PAT: 5.6 (Loss to Profit YoY | Loss to Profit QoQ) ■ EPS (INR): 0.04 (Loss to Profit YoY | Loss to Profit QoQ)
Original exchange filing (PDF)
More announcements from Piramal Pharma Ltd
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HDFC Mutual Fund · 31 Oct 2026
- Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI LODR Regulations, 2015 · 30 Oct 2026
- Please find enclosed details of Earning call Transcript held on 28th October 2026. · 30 Oct 2026
- Please find enclosed intimation of audio recordings of the conference call held today 28th October, 2026. · 28 Oct 2026
- Please find enclosed Investor presentation for quarter ended 30 September, 2026 · 28 Oct 2026
- Please find enclosed Press release for quarter ended 30 September, 2026 · 28 Oct 2026
- Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 28 Oct 2026
- Please find enclosed unaudited financial results for Q2 FY 27 · 28 Oct 2026
